Renovacor (Renovacor) Earnings Power Value (EPV) : $2.99 (As of Sep22)

View and export this data going back to 2021. Start your Free Trial

What is Renovacor Earnings Power Value (EPV)?

As of Sep22, Renovacor's earnings power value is $2.99. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.

Renovacor Earnings Power Value (EPV) Historical Data

The historical data trend for Renovacor's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor Earnings Power Value (EPV) Chart

Renovacor Annual Data

Trend

Dec20

Dec21

Earnings Power Value (EPV)

Renovacor Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Earnings Power Value (EPV)	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Renovacor's Earnings Power Value (EPV)

For the Biotechnology subindustry, Renovacor's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renovacor's Earnings Power Value (EPV) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovacor's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Renovacor's Earnings Power Value (EPV) falls into.

Renovacor Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Renovacor (AMEX:RCOR) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.

Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.

Renovacor Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of Renovacor's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovacor (Renovacor) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » Earnings Power Value (EPV)

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 8142, Greenwich, CT, USA, 06836

Website

https://www.renovacor.com

Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.

Executives

Joseph S Carroll	officer: Chief Accounting Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino	director	C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau	director	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr.	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll	officer: Chief Financial Officer
Jonas Grossman	director	17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa	director	17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook	director, officer: Chief Executive Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen	officer: Chief Scientific Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd.	10 percent owner	C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran	officer: Chief Medical Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco	officer: Interim CFO